ClinicalTrials.Veeva

Menu

HDV Screening Study

G

Grace Lai Hung Wong

Status

Enrolling

Conditions

Hepatitis D Virus Infection

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT06889805
SPEARHEAD 2024

Details and patient eligibility

About

This is a territory-wide cross-sectional study of all individuals living with HIV/HBV coinfection and HBV-related HCC.

Full description

Chronic hepatitis B virus (HBV) infection remains endemic in Hong Kong with an estimated prevalence of 6.2% in the recent Population Health Survey 2020-2022.1 The estimated prevalence of chronic HBV infection among individuals living with HIV is 8%.2 Yet, no data are available concerning the disease burden of hepatitis delta virus (HDV) among individuals living with HIV/HBV coinfection.

Enrollment

300 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Individuals with HIV infection, i.e. anti-HIV or HIV RNA positive; AND
  2. Individuals with chronic hepatitis B, i.e. hepatitis B surface antigen (HBsAg) or HBV DNA positive for two times at least 6 months apart; AND
  3. Aged 18 years old or above.
  4. Written or verbal consent obtained

Exclusion criteria

  1. Refusal to consent
  2. Age < 18 years

Trial contacts and locations

1

Loading...

Central trial contact

Angel Chim

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems